Pfizer reaffirmed 2026 guidance after CFO exit, shares trade near recent lows

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:22.

Pfizer Inc. (US7170811035) has reaffirmed its 2026 financial guidance even as it undergoes a leadership change in the finance function. The New York-based pharma heavyweight, listed on the NYSE and included in the S&P 500, faces muted share sentiment after its chief financial officer’s exit, according to Zacks.

What Zacks reports on Pfizer

Zacks notes that Pfizer shares traded lower following the departure of CFO David Denton while management reiterated its guidance for 2026, signaling continuity in the company’s medium-term financial framework despite the executive change. Zacks analysis on the CFO exit and guidance reaffirmation The research house currently assigns Pfizer a Rank #3 (Hold), pointing to a neutral stance in the near term.

According to MarketBeat data, Pfizer shares closed at 23.64 US dollars on the NYSE on June 25, 2026, down about 1.7 percent on the day, with extended trading quotes modestly higher in pre-market activity. MarketBeat overview of Pfizer’s latest share price Since the start of the year, the stock has retreated roughly in the mid-single-digit percentage range, reflecting investor caution on post-pandemic earnings and the pipeline.

Analyst consensus and valuation picture

Analyst estimates compiled by Benzinga show a 12-month price target range for Pfizer of 25 to 33 US dollars, with the average target at around 27.29 US dollars, implying upside of roughly 15 percent from the latest close. Benzinga report on Pfizer’s analyst price targets The dispersion of targets suggests a mixed view, with some houses seeing recovery potential while others remain cautious on the pace of earnings normalization.

In valuation terms, Pfizer currently trades in the low-20s US dollars, equating to a price-to-earnings multiple in the mid-teens on forward estimates, based on consensus data from major market platforms. MarketBeat valuation metrics for Pfizer That leaves the shares at a discount to several large-cap pharma peers such as Johnson & Johnson and Merck, though the discount reflects post-COVID revenue normalization and the need for new growth drivers.

The business behind Pfizer’s revenues

Pfizer generates the bulk of its revenue from prescription drugs and vaccines across oncology, immunology, cardiology and infectious diseases, with annual sales around 60 billion US dollars in recent years. Benzinga profile of Pfizer’s business mix Key products include the pneumococcal vaccine Prevnar 13, cardiology therapies such as Vyndaqel and Eliquis, and a portfolio of oncology medicines, all sold to healthcare systems globally.

Where the Pfizer stock trades today

Pfizer shares (US7170811035) trade on the NYSE at 23.64 US dollars as of 2026-06-25, 15:59 Eastern Time, according to MarketBeat data. MarketBeat latest Pfizer quote Extended trading quotes show 23.80 US dollars in early pre-market indications.

This article is for informational purposes only and does not contain investment advice or recommendations. All data are based on sources cited and may change over time.